Progress of chimeric antigen receptor T cells in treatment of B-cell lymphoma
10.3760/cma.j.cn115356-20201204-00290
- VernacularTitle:嵌合抗原受体T细胞治疗B细胞淋巴瘤研究进展
- Author:
Kaixin DU
;
Wei XU
- From:
Journal of Leukemia & Lymphoma
2021;30(2):74-77
- CountryChina
- Language:Chinese
-
Abstract:
B-cell lymphoma (BCL) is a highly heterogeneous malignant tumor. In recent years, although the remission rate of BCL patients has been improved with the improvement of diagnosis and treatment methods, some patients still relapse and become refractory. Chimeric antigen receptor T cells (CAR-T) is a novel therapy. At present, CD19 CAR-T has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma. At the 62nd American Society of Hematology Annual Meeting, a number of studies reported the latest progress of CAR-T in the treatment of relapsed/refractory BCL.
